mak - exactly right. You can be certain that the co has had a hard look at revenue forecasts including revenue from all sources, including Elixia, as well as milestone and other payments on projects that we as outsiders have no handle on. Looking at cash on hand, forecast revenues, trial cash flow requirements, other cash requirements, etc. the company has been pretty clear: that it planned to fund oxycodone to the maximum extent possible from revenue.
Can they take it all the way to completion?
Maybe, but probably not. Still, there is no reason to think that they are going to raise capital unless and until it is necessary. They would certainly not postpone the start of the trials until every future uncertainty has been resolved.
my chart, page-48
-
- There are more pages in this discussion • 17 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add AVE (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.3¢ |
Change
0.000(0.00%) |
Mkt cap ! $7.923M | |||
| Open | High | Low | Value | Volume |
| 0.3¢ | 0.3¢ | 0.3¢ | $1.096K | 438.4K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 47 | 86702619 | 0.2¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.3¢ | 59480558 | 19 |
View Market Depth
| Last trade - 15.24pm 16/08/2024 (20 minute delay) ? |
| AVE (ASX) Chart |